A 14-year-old male presented in 1991 with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria. The patient was maintained on transfusion support until July 1998, when he received an ...
OBJECTIVE: To determine the most effective, evidence-based approach to the use of platelet transfusions in patients with cancer. OUTCOMES: Outcomes of interest included prevention of morbidity and ...
PTP is characterized by the development of severe, sudden and self-limiting thrombocytopenia occurring 5-10 days after a blood transfusion. The recipients always have a history of sensitization, ...
Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...
The FDA has granted approval to the menin inhibitor ziftomenib (Komzifti) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations with no ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--LightIntegra Technology (LIT), developer of the first 5-minute test for platelet activation status, announced that it has received $5.3 million USD in ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16 th Annual Hemovigilance report by the French National Agency for Medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback